Mercè Brunet

TL;DR: Chemoembolization using DEBs is an effective procedure with a favorable pharmacokinetic profile and after a median follow-up of 27.6 months, 1- and 2-year survival is 92.5% and 88.9%, respectively.

TL;DR: The importance of obtaining multicenter prospective trials to assess the efficacy of alternative strategies to TAC trough concentrations is emphasized, and single time points, limited sampling strategies, and area under concentration-time curve have all been considered to determine the most appropriate sampling procedure that correlates with efficacy.

TL;DR: It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.

TL;DR: MPA exposure should be measured and doses should be adjusted accordingly to achieve optimal clinical outcomes and limited sampling strategies to estimate MPA exposure from EC-MPS have not yet been well developed and fully evaluated, nor have accurate Bayesian estimators been reported.

TL;DR: EVR trough concentrations (C0) demonstrate a good relationship with overall exposure, providing a simple and reliable index for TDM, and a fully validated liquid chromatography tandem mass spectrometry assay is the preferred method for determination of EVR C0.